Topics:

Tremelimumab trial discontinued

Tremelimumab trial discontinued

NEW YORK—Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. “We will continue to assess the study data to understand the clinical benefit seen in some patients who received tremelimumab,” said Pfizer’s Charles Baum, MD, PhD.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.